CARM OTC
Carisma Therapeutics, Inc.
1W: -37.5%
1M: -28.6%
3M: -91.5%
YTD: -98.9%
1Y: -99.8%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Weekly Expected Move ±41.6%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
20 relationships20
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2022-07-18
Earliest Filing
2025-09-18
Latest Filing
target: 8
acquirer: 5
partner: 4
licensee: 2
investor: 1
Counterparties (Filed by CARM)
20 relationshipsCompanies named in CARM's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| ModernaTX, Inc. | MRNA | partner | Amendment to Collaboration and License Agreement terminating financial obligations | 2025-09-18 | View |
| Ocugen, Inc. | OCGN | target | Target of terminated Merger Agreement and investor in subscription agreement | 2025-09-18 | View |
| OrthoCellix, Inc. | — | target | Wholly-owned subsidiary of Ocugen and target of terminated Merger Agreement | 2025-09-18 | View |
| Ocugen, Inc. | OCGN | investor | Agreed to purchase $5.0 million of common stock in a private placement as part of the Concurrent Investment. | 2025-08-29 | View |
| OrthoCellix, Inc. | — | target | Target of the merger with Carisma Therapeutics Inc.; wholly-owned subsidiary of Ocugen. | 2025-08-29 | View |
| Ocugen, Inc. | OCGN | target | Target company in the merger agreement with Carisma Therapeutics Inc. | 2025-06-23 | View |
| OrthoCellix, Inc. | — | target | Wholly-owned subsidiary of Ocugen and the primary target company in the merger agreement. | 2025-06-23 | View |
| Azalea Merger Sub, Inc. | — | partner | Wholly-owned subsidiary of Carisma Therapeutics Inc. and the merger subsidiary entering the agreement. | 2025-06-23 | View |
| ModernaTX, Inc. | MRNA | partner | Counterparty to an existing collaboration and license agreement referenced in the Contingent Value Rights Agreement. | 2025-06-23 | View |
| ModernaTX, Inc. | MRNA | partner | Strategic collaboration for in vivo engineered CAR-M therapeutics | 2023-03-08 | View |
| University of Pennsylvania | — | licensee | License agreement for CAR-M related patents and know-how | 2023-03-08 | View |
| New York University | — | licensee | License agreement for Vpx-LV related patents and know-how | 2023-03-08 | View |
| F. Hoffmann-La Roche Ltd | ROG | acquirer | Asset purchase agreement for Carisma's assets | 2023-03-08 | View |
| Hoffman-La Roche Inc. | ROG | acquirer | Asset purchase agreement for Carisma's assets | 2023-03-08 | View |
| Roche | ROG | acquirer | Asset purchase agreement for Carisma's assets | 2023-03-08 | View |
| Vicineum | — | target | Non-cash assets sold in connection with the Merger | 2023-03-08 | View |
| CARISMA Therapeutics Inc. | CARM | target | Target company in the merger agreement with Sesen Bio, Inc. | 2023-02-14 | View |
| CARISMA Therapeutics Inc. | CARM | target | Target company in the merger agreement with Sesen Bio, Inc. | 2022-12-29 | View |
| F. Hoffmann-La Roche Ltd | — | acquirer | Purchased all patent rights and know-how related to monoclonal antibody EBI-031 and other IL-6 technology for up to $70 | 2022-07-18 | View |
| Hoffman-La Roche Inc. | — | acquirer | Co-signatory to the asset purchase agreement with F. Hoffmann-La Roche Ltd to acquire Sesen Bio's intellectual property. | 2022-07-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2025-12-05 | Notice of Delisting or Transfer; Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-15 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-10-09 | Notice of Delisting or Transfer | View | |
| 2025-09-18 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Other Events | Agreement | View |
| 2025-08-29 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Changes in Contro | Agreement | View |
| 2025-08-08 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-07-15 | Notice of Delisting or Transfer | View | |
| 2025-06-23 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-06-12 | Other Events | View | |
| 2025-04-16 | Notice of Delisting or Transfer | View | |
| 2025-01-13 | Other Events | View | |
| 2025-01-10 | Notice of Delisting or Transfer | View | |
| 2024-12-26 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-12-09 | Costs Associated with Exit or Disposal Activities; Departure/Election of Directors; Appointment of O | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-30 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-10-11 | Notice of Delisting or Transfer | View | |
| 2024-08-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-07-09 | Other Events; Financial Statements and Exhibits | View | |
| 2024-07-02 | Costs Associated with Exit or Disposal Activities | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR